Isolithocholic acid 3β-Hydroxy-5β-cholanic acid; 3-Epilithocholic acid; β-Lithocholic acid,98.0%
产品编号:Bellancom-B0172B| CAS NO:1534-35-6| 分子式:C24H40O3| 分子量:376.57
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
Isolithocholic acid 3β-Hydroxy-5β-cholanic acid; 3-Epilithocholic acid; β-Lithocholic acid
产品介绍 | Isolithocholic acid (β-Lithocholic acid) 是石胆酸的一种同分异构体。Isolithocholic acid 是一种胆酸,由 Lithocholic acid 或 Lithocholic acid 3α-sulfate 经微生物代谢形成。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | Isolithocholic acid (β-Lithocholic acid) is an isomer of Lithocholic acid. Isolithocholic acid, a bile acid, is formed by microbial metabolism of Lithocholic acid or Lithocholic acid 3α-sulfate. | ||||||||||||||||
体外研究 |
Isolithocholic acid at 0.01 % does not inhibit spore germination and outgrowth of CF5 and M120, but it significantly inhibits at the higher concentration (0.1 %). Isolithocholic acid (0.00003 %) prevents growth of CD196, M68, CF5, 630, and BI9 and significant decreases strains CF5, BI9, M120, and 630 in toxin activity. Isolithocholic acid (0.0003 %) makes that all strains displays a significant decrease in toxin activity, except for R20291 and M120. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
The levels of fecal Isolithocholic acid shows obvious decreases from day 28 onward in the high fat diet (HFD) group compared with rats fed a normal diet[4]. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
The levels of fecal Isolithocholic acid shows obvious decreases from day 28 onward in the high fat diet (HFD) group compared with rats fed a normal diet[4]. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 28.57 mg/mL (75.87 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
参考文献 |
|